Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 3/20 | 0.52 |
| ▸ | FPR1 | P21462 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 2/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19995225 | 0.85 | REN (0.54) | RENFPR1MAOAKDM1AMAOB | |
| SCHEMBL14432358 | 0.82 | REN (0.52) | RENFPR1MAOAKDM1AMAOB | |
| SCHEMBL28103960 | 0.82 | REN (0.52) | RENFPR1MAOAKDM1AMAOB | |
| SCHEMBL17474540 | 0.78 | FPR1 (0.52) | RENFPR1KMT2AMAOAKDM1A | |
| SCHEMBL8448724 | 0.76 | REN (0.56) | RENFPR1MEN1KMT2AMAOA | |
| SCHEMBL14256225 | 0.75 | REN (0.45) | RENFPR1 | |
| SCHEMBL14256183 | 0.75 | REN (0.53) | RENFPR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL16874612 | 0.74 | REN (0.52) | RENFPR1MEN1KMT2AMAOA | |
| SCHEMBL16874609 | 0.74 | REN (0.52) | RENFPR1MEN1KMT2AMAOA | |
| SCHEMBL16874548 | 0.74 | REN (0.52) | RENFPR1MEN1KMT2AMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2163245-A1 | Renin inhibitors for the treatment of psoriasis | Novartis Ag (CH) | 2010-03-17 | — | — | EP | disclosed |
| EP-1816122-A2 | 3,4,5-substituted piperidines as therapeutic compounds | Speedel Experimenta AG (CH) | 2007-08-08 | — | — | EP | disclosed |